1. Pink Sheet
  2. >>Drug Safety

US FDA’s Marks Criticizes UK For ‘Rushing’ Adverse Event Announcement On COVID Vaccine

 
• By Derrick Gingery

The allergic reactions ‘just occurred yesterday and they haven’t been fully investigated,’ CBER Director Marks says.

popcorn
Is the crowded theater on fire, or is the popcorn just burnt? • Source: Shutterstock

Peter Marks, director of the US Food and Drug Administration’s Center for Biologics Evaluation and Research, criticized the UK’s quick release of a safety notice on adverse events about Pfizer/BioNTech’s COVID vaccine, saying there was too little context for public understanding.

After reports of two frontline national health service (NHS) staff experiencing allergic reactions related to the vaccine, named BNT162b2, the UK’s Medicines and Healthcare products Regulatory Authority has now advised anyone with a history of significant allergic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

Biomarker Negativity At Issue In Pfizer Bid To Broaden Talzenna CRPC Claim

 
• By Bridget Silverman

The FDA questioned Pfizer’s reliance on a “large, incompletely defined” subgroup of castration-resistant prostate cancer patients without known HRR gene alterations in its review of the proposed expansion of Talzenna’s first-line indication for HRR-mutated CRPC to an all-comers population.

UroGen’s Mitomycin: Are Randomized Trials For Bladder Cancer Necessary?

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee will vote on the risk-benefit of UGN-102 for low-grade, intermediate-risk, non-muscle invasive bladder cancer based on data from a single-arm trial, but the FDA also seeks input on requiring randomized studies for future treatments.